Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Provincial Institute of Materia Medica is a China-based drug research institute in Nanjing that appears to operate both as a research organization and as a preclinical services provider. Publicly available information indicates the institute conducts medicinal chemistry, natural drug research, pharmacology, toxicology, and analytical studies, and it also performs general, reproductive, genetic, and carcinogenic toxicology studies. The organization has been described as part of Nanjing Tech University and as one of the early GLP-certified laboratories in China. Patent records suggest activity in small-molecule drug discovery, process chemistry, and formulations spanning oncology supportive care, metabolic disease, cardiovascular disease, and natural-product-derived medicines. Specific marketed products or a clearly disclosed modern clinical pipeline were not identified from readily available public sources.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu Provincial Institute of Materia Medica.